Missouri Autism Centers of Excellence Collaborative (MACEC): SEED Early Development Study

摘要 本项目是一个重点流行病学研究的继续 自闭症和发育障碍流行病学中心的能力 （CADDRE）网络，并实施早期探索研究第3阶段 发展SEED研究的持续目标是描述自闭症的特征， 行为表型和相关的发育、医学和行为状况 自闭症的症状了解自闭症的遗传和环境风险因素。的 本申请的目的如下：1.执行种子研究的第三阶段 保留核心研究设计，改进招募工作， 在一个新的中西部种子网站的数据收集协议减少。以下 3期研究将保留核心研究设计的各个方面：a）病例对照研究 一个ASD病例组的多源确定设计，一个非ASD病例组 发育障碍（DD）对照组和基于人群的（POP） 对照组，B）所有参与者发育状态的临床确认 使用标准化评估方案，以及c）收集临床、遗传和 环境数据。加强征聘工作将包括积极的后续行动 受邀参与者的程序。数据收集将得到简化， 第2阶段，主要是通过消除儿科和新生儿病历摘要， 所有三个参与者组和缩减DD对照组收集的数据。 2.进一步增加总SEED合并样本量，以增强SEED的分析 通过获得完整的数据来研究罕见暴露和ASD亚型的可能性 收集125 ASD儿童，125 DD儿童和125 POP儿童在我们的网站。 在所有预期的第3阶段站点实现这些目标将增加总SEED ASD 样本约2000名儿童，这将加强检查罕见的 暴露和可能与ASD病因学相关的适度关联。

Abstract This project is a focused on the continuation of the epidemiological research capability of the Centers for Autism and Developmental Disabilities Epidemiology (CADDRE) network with implementation of Phase 3 of the Study to Explore Early Development. The ongoing objectives of the SEED study are to characterize the autism behavioral phenotype and associated developmental, medical and behavioral conditions of autism. and to understand the genetic and environmental risk factors of Autism. The aims of this application are as follows: 1. Implement a third Phase of the SEED study preserving the core study design with enhancements to improve recruitment and a reduction in the data collection protocol in a new Midwestern SEED site. The following aspects of the core study design will be preserved in Phase 3: a) a case-control study design with multiple- source ascertainment of an ASD case group, a non- ASD developmental disability (DD) comparison group and a population-based (POP) comparison group, b) clinical confirmation of developmental status of all participants using a standardized assessment protocol, and c) collection of clinical, genetic and environmental data. Recruitment enhancements will include active follow-up procedures for invited participants. Data collection will be streamlined, compared to Phase 2, primarily by eliminating pediatric and neonatal medical record abstraction for all three participant groups and curtailing data collected for the DD comparison group. 2. Further increase the total SEED pooled sample size to enhance SEED's analytic potential to investigate rare exposures and ASD subtypes by achieving complete data collection on 125 ASD children, 125 DD children and 125 POP children within our site. Reaching these targets at all anticipated Phase 3 sites will increase the total SEED ASD sample to approximately 2000 children which will enhance the examination of rare exposures and modest associations potentially relevant to the etiology of ASD.